Trials / Completed
CompletedNCT03695510
Afatinib and Pembrolizumab for Head and Neck Squamous Cell Carcinoma (ALPHA Study)
Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, A Single-Arm, Phase II Study (ALPHA Study)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- National Taiwan University Hospital · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The primary objectives of the trial is to examine the toxicities and efficacies of afatinib and pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma.
Detailed description
It is a single arm, phase II, single center, prospective, open label clinical trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Afatinib Oral Tablet | 40mg oral, daily, continuously |
| DRUG | Pembrolizumab Injection | 200mg, intra-venous injection, every 3 weeks, for 35 cycles |
Timeline
- Start date
- 2019-01-24
- Primary completion
- 2022-04-14
- Completion
- 2022-04-14
- First posted
- 2018-10-04
- Last updated
- 2022-04-21
Locations
1 site across 1 country: Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03695510. Inclusion in this directory is not an endorsement.